Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.39 USD | +2.39% | +5.68% | +1.38% |
05-13 | Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test | MT |
05-13 | Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.38% | 9.83B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Goldman Sachs Upgrades Qiagen to Buy From Neutral, Raises Price Target to $50 From $47